other material
confidence high
sentiment positive
materiality 0.80
Vera Therapeutics reports positive 72-week Phase 2b atacicept data with eGFR stabilization in IgAN
Vera Therapeutics, Inc.
- Atacicept 150mg for 72 weeks: 62% reduction in Gd-IgA1, hematuria to 19%, 48% reduction in UPCR (PP analysis).
- eGFR stable with 0 mL/min/1.73m² change from baseline; placebo-to-atacicept switchers halted eGFR decline (-3.2 vs -4.9 at 36wks).
- Safety consistent with prior trials; generally well-tolerated in OLE.
- Phase 3 ORIGIN 3 enrollment on track for H2 2024; topline data expected H1 2025; BLA submission planned H2 2025.